Investing in the future

There has never been a greater need for advanced organ preservation solutions, and the need is growing. More than 200,000 patients in Europe and the US await lifesaving organ transplants. Although there has been a general increase in the availability of donor organs due to extensive educational programmes, UK transplant statistics show a slight decline in the number of donor organs, and transplants have fallen for the first time in many years. The requirement for organ transplantation will continue to rise based on an aging global society, and an increase in the number of chronic diseases and organ failure worldwide. It is more important than ever to ensure that each organ is afforded the best preservation solution possible. 

OPSL are well placed to make a dramatic impact in the organ preservation field with two advanced cold static organ preservation solutions (LS-A™ and LS-T™), which have outperformed current ‘Gold Standard’ solutions in all pre-clinical trials. We are working closely with the NHS as a platform for a worldwide launch. Our solutions’ improved handling due to lower viscosity is seen as an important lever in the rapid uptake by surgeons and healthcare providers. Further to this, we have a strong IP position with a newly filed patent providing the potential of a further 20 years of patent life and further IP to support product expansion across the transplant area. We have advanced strategic partnership discussions with key players in multiple markets, suggesting diverse options for OPSL’s future.